Cargando…

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data

BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Isra...

Descripción completa

Detalles Bibliográficos
Autores principales: Tenenbaum, Alexander, Medvedofsky, Diego, Fisman, Enrique Z., Bubyr, Liudmila, Matetzky, Shlomi, Tanne, David, Klempfner, Robert, Shemesh, Joseph, Goldenberg, Ilan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327654/
https://www.ncbi.nlm.nih.gov/pubmed/22523582
http://dx.doi.org/10.1371/journal.pone.0035298
_version_ 1782229673696034816
author Tenenbaum, Alexander
Medvedofsky, Diego
Fisman, Enrique Z.
Bubyr, Liudmila
Matetzky, Shlomi
Tanne, David
Klempfner, Robert
Shemesh, Joseph
Goldenberg, Ilan
author_facet Tenenbaum, Alexander
Medvedofsky, Diego
Fisman, Enrique Z.
Bubyr, Liudmila
Matetzky, Shlomi
Tanne, David
Klempfner, Robert
Shemesh, Joseph
Goldenberg, Ilan
author_sort Tenenbaum, Alexander
collection PubMed
description BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Israeli Surveys (ACSIS) and were treated on discharge with a fibrate (mainly bezafibrate) and statin combination vs. statin alone. METHODS: The study population comprised 8,982 patients from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment waves who were alive on discharge and received statin. Of these, 8,545 (95%) received statin alone and 437 (5%) received fibrate/statin combination. MACE was defined as a composite measure of death, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke and urgent revascularization. RESULTS: Patients from the combination group were younger (58.1±11.9 vs. 62.9±12.6 years). However, they had significantly more co-morbidities (hypertension, diabetes), current smokers and unfavorable cardio-metabolic profiles (with respect to glucose, total cholesterol, triglyceride and HDL-cholesterol). Development of MACE was recorded in 513 (6.0%) patients from the statin monotherapy group vs. 13 (3.2%) from the combination group, p = 0.01. 30-day re-hospitalization rate was significantly lower in the combination group: 68 (15.6%) vs. 1691 (19.8%) of patients, respectively; p = 0.03. Multivariable analysis identified the fibrate/statin combination as an independent predictor of reduced risk of MACE with odds ratio of 0.54, 95% confidence interval 0.32–0.94. CONCLUSION: A significantly lower risk of 30-day MACE rate was observed in patients receiving combined fibrate/statin treatment following ACS compared with statin monotherapy. However, caution should be exercised in interpreting these findings taking into consideration baseline differences between our observational study groups.
format Online
Article
Text
id pubmed-3327654
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33276542012-04-20 Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data Tenenbaum, Alexander Medvedofsky, Diego Fisman, Enrique Z. Bubyr, Liudmila Matetzky, Shlomi Tanne, David Klempfner, Robert Shemesh, Joseph Goldenberg, Ilan PLoS One Research Article BACKGROUND: The effect of combination of fibrate with statin on major adverse cardiovascular events (MACE) following acute coronary syndrome (ACS) hospitalization is unclear. The main aim of this study was to investigate the 30-day rate of MACE in patients who participated in the nationwide ACS Israeli Surveys (ACSIS) and were treated on discharge with a fibrate (mainly bezafibrate) and statin combination vs. statin alone. METHODS: The study population comprised 8,982 patients from the ACSIS 2000, 2002, 2004, 2006, 2008 and 2010 enrollment waves who were alive on discharge and received statin. Of these, 8,545 (95%) received statin alone and 437 (5%) received fibrate/statin combination. MACE was defined as a composite measure of death, recurrent MI, recurrent ischemia, stent thrombosis, ischemic stroke and urgent revascularization. RESULTS: Patients from the combination group were younger (58.1±11.9 vs. 62.9±12.6 years). However, they had significantly more co-morbidities (hypertension, diabetes), current smokers and unfavorable cardio-metabolic profiles (with respect to glucose, total cholesterol, triglyceride and HDL-cholesterol). Development of MACE was recorded in 513 (6.0%) patients from the statin monotherapy group vs. 13 (3.2%) from the combination group, p = 0.01. 30-day re-hospitalization rate was significantly lower in the combination group: 68 (15.6%) vs. 1691 (19.8%) of patients, respectively; p = 0.03. Multivariable analysis identified the fibrate/statin combination as an independent predictor of reduced risk of MACE with odds ratio of 0.54, 95% confidence interval 0.32–0.94. CONCLUSION: A significantly lower risk of 30-day MACE rate was observed in patients receiving combined fibrate/statin treatment following ACS compared with statin monotherapy. However, caution should be exercised in interpreting these findings taking into consideration baseline differences between our observational study groups. Public Library of Science 2012-04-16 /pmc/articles/PMC3327654/ /pubmed/22523582 http://dx.doi.org/10.1371/journal.pone.0035298 Text en Tenenbaum et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Tenenbaum, Alexander
Medvedofsky, Diego
Fisman, Enrique Z.
Bubyr, Liudmila
Matetzky, Shlomi
Tanne, David
Klempfner, Robert
Shemesh, Joseph
Goldenberg, Ilan
Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title_full Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title_fullStr Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title_full_unstemmed Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title_short Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
title_sort cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: acute coronary syndrome israeli surveys data
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327654/
https://www.ncbi.nlm.nih.gov/pubmed/22523582
http://dx.doi.org/10.1371/journal.pone.0035298
work_keys_str_mv AT tenenbaumalexander cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT medvedofskydiego cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT fismanenriquez cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT bubyrliudmila cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT matetzkyshlomi cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT tannedavid cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT klempfnerrobert cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT shemeshjoseph cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata
AT goldenbergilan cardiovasculareventsinpatientsreceivedcombinedfibratestatintreatmentversusstatinmonotherapyacutecoronarysyndromeisraelisurveysdata